In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates.
In vitro susceptibilities of 100 clinical dermatophyte isolates belonging to five species from Iran toward lanoconazole and luliconazole were compared with ten other antifungal agents including econazole, itraconazole, miconazole, fluconazole, griseofulvin, butenafine, terbinafine, caspofungin, anidulafungin and tolnaftate. MIC and MEC values were analyzed according to CLSI M38-A2 document. The isolates were previously identified to the species level using PCR-RFLP on ITS rDNA region. The range of luliconazole and lanoconazole minimum inhibitory concentrations (MICs) was 0.016-0.032 and 0.063-1 μg/ml, respectively for dermatophyte species. Luliconazole and lanoconazole revealed potent activity against all dermatophyte isolates. Anidulafungin, caspofungin, and luliconazole showed the best activity with the lowest geometric mean 0.01, 0.016, and 0.018 μg/ml, respectively, followed by tolnaftate (0.06 μg/ml), terbinafine (0.07 μg/ml), itraconazole (0.183 μg/ml), butenafine (0.188 μg/ml), econazole (0.20 μg/ml), lanoconazole (0.24 μg/ml), griseofulvin (1.28 μg/ml), miconazole (2.34 μg/ml) and fluconazole (15.34 μg/ml). The current study demonstrated luliconazole and lanoconazole displayed excellent activity against all dermatophyte isolates, although the majority of dermatophyte isolates showed low susceptibility to griseofulvin and very low to miconazole, and fluconazole.
Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
Nesa
N
Baghi
Invasive Fungi Research Center (IFRC), Department of Medical Mycology and Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Tahereh
T
Shokohi
Invasive Fungi Research Center (IFRC), Department of Medical Mycology and Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Hamid
H
Badali
Laboratory of Space and Environmental Medicine, Graduate School of Medicine, Teikyo University, Japan; Asia International Institute of Infectious Diseases Control, Teikyo University, Japan; Teikyo University Institute of Medical Mycology, Tokyo, Japan.
Koichi
K
Makimura
Department of Medical Mycology, School of Medicine, Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Ali
A
Rezaei-Matehkolaei
Department of Microbiology and Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Maryam
M
Abdollahi
Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
Mojtaba
M
Didehdar
Invasive Fungi Research Center (IFRC), Department of Medical Mycology and Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Iman
I
Haghani
Invasive Fungi Research Center (IFRC), Department of Medical Mycology and Parasitology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran mabastabar@gmail.com.
Mahdi
M
Abastabar
D000935:Antifungal Agents / Q000494:pharmacology*; D003883:Arthrodermataceae / Q000145:classification / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D021903:DNA, Ribosomal Spacer / Q000737:chemistry / Q000235:genetics; D003881:Dermatomycoses / Q000382:microbiology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D007492:Iran; D008826:Microbial Sensitivity Tests; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length
D000935:Antifungal Agents; D021903:DNA, Ribosomal Spacer; D007093:Imidazoles; C072774:latoconazole; C112528:luliconazole
Dermatophytes; in vitro antifungal susceptibility; lanoconazole; luliconazole